BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 38653804)

  • 1. A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma.
    Durand M; Cabaud Gibouin V; Duplomb L; Salmi L; Caillot M; Sola B; Camus V; Jardin F; Garrido C; Jego G
    J Exp Clin Cancer Res; 2024 May; 43(1):148. PubMed ID: 38773631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual Inhibition of CDK4/6 and XPO1 Induces Senescence With Acquired Vulnerability to CRBN-Based PROTAC Drugs.
    Wang H; Yuan S; Zheng Q; Zhang S; Zhang Q; Ji S; Wang W; Cao Y; Guo Y; Yang X; Geng H; Yang F; Xi S; Jin G; Zhang J; Gao Q; Bernards R; Qin W; Wang C
    Gastroenterology; 2024 Jun; 166(6):1130-1144.e8. PubMed ID: 38262581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer models.
    Gravina GL; Mancini A; Sanita P; Vitale F; Marampon F; Ventura L; Landesman Y; McCauley D; Kauffman M; Shacham S; Festuccia C
    BMC Cancer; 2015 Dec; 15():941. PubMed ID: 26620414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The nuclear export protein exportin-1 in solid malignant tumours: From biology to clinical trials.
    Lai C; Xu L; Dai S
    Clin Transl Med; 2024 May; 14(5):e1684. PubMed ID: 38783482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppressing activity of tributyrin on hepatocarcinogenesis is associated with inhibiting the p53-CRM1 interaction and changing the cellular compartmentalization of p53 protein.
    Ortega JF; de Conti A; Tryndyak V; Furtado KS; Heidor R; Horst MA; Fernandes LH; Tavares PE; Pogribna M; Shpyleva S; Beland FA; Pogribny IP; Moreno FS
    Oncotarget; 2016 Apr; 7(17):24339-47. PubMed ID: 27013579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma.
    Camus V; Stamatoullas A; Mareschal S; Viailly PJ; Sarafan-Vasseur N; Bohers E; Dubois S; Picquenot JM; Ruminy P; Maingonnat C; Bertrand P; Cornic M; Tallon-Simon V; Becker S; Veresezan L; Frebourg T; Vera P; Bastard C; Tilly H; Jardin F
    Haematologica; 2016 Sep; 101(9):1094-101. PubMed ID: 27479820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDK4/6 inhibition augments anti-tumor efficacy of XPO1 inhibitor selinexor in natural killer/T-cell lymphoma.
    Wang Y; Chen J; Gao Y; Chai KXY; Hong JH; Wang P; Chen J; Yu Z; Liu L; Huang C; Taib NAM; Lim KMH; Guan P; Chan JY; Huang D; Teh BT; Li W; Lim ST; Yu Q; Ong CK; Huang H; Tan J
    Cancer Lett; 2024 Jun; ():217080. PubMed ID: 38908542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nucleo-cytoplasmic transport as a therapeutic target of cancer.
    Gravina GL; Senapedis W; McCauley D; Baloglu E; Shacham S; Festuccia C
    J Hematol Oncol; 2014 Dec; 7():85. PubMed ID: 25476752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
    Gandhi UH; Senapedis W; Baloglu E; Unger TJ; Chari A; Vogl D; Cornell RF
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):335-345. PubMed ID: 29610030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways.
    Chakravarti N; Boles A; Burzinski R; Sindaco P; Isabelle C; McConnell K; Mishra A; Porcu P
    Sci Rep; 2024 Apr; 14(1):9305. PubMed ID: 38653804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.
    Zheng Y; Gery S; Sun H; Shacham S; Kauffman M; Koeffler HP
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):487-95. PubMed ID: 25030088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth.
    Wettersten HI; Landesman Y; Friedlander S; Shacham S; Kauffman M; Weiss RH
    PLoS One; 2014; 9(12):e113867. PubMed ID: 25461627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines.
    Breit MN; Kisseberth WC; Bear MD; Landesman Y; Kashyap T; McCauley D; Kauffman MG; Shacham S; London CA
    BMC Vet Res; 2014 Jul; 10():160. PubMed ID: 25022346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
    De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
    Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of XPO1 with KPT-330 induces autophagy-dependent apoptosis in gallbladder cancer by activating the p53/mTOR pathway.
    Zhao C; Yang ZY; Zhang J; Li O; Liu SL; Cai C; Shu YJ; Pan LJ; Gong W; Dong P
    J Transl Med; 2022 Sep; 20(1):434. PubMed ID: 36180918
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.